<DOC>
	<DOCNO>NCT00002999</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one drug combine chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness chemotherapy plus radiation therapy treat patient advanced cancer nasopharynx .</brief_summary>
	<brief_title>S9715 , Chemotherapy Radiation Therapy Treating Patients With Advanced Cancer Nasopharynx</brief_title>
	<detailed_description>OBJECTIVES : I . Gather additional information experience regarding preferred treatment clinical trial SWOG-8892 , chemoradiation patient advance nasopharyngeal cancer ( NPC ) . II . Evaluate survival progression-free survival pattern tumor failure new group patient . III . Assess severe lethal toxicity may encounter regimen employ widely . IV . Collect NPC tumor specimen ongoing future clinical correlative research . OUTLINE : Patients receive cisplatin intravenous infusion day 1 15-20 minute period . This repeat every 21 day first three initial treatment . Patients also receive radiation therapy daily five time week cycle treatment . Approximately three week completion treatment , patient give cisplatin intravenous infusion 15-20 minute low dose . On day cisplatin infusion , patient receive fluorouracil continuous intravenous infusion 24 hour 4 day row . This repeat every 28 day total 3 treatment . Patients follow death . PROJECTED ACCRUAL : 100 patient accrue .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven nasopharyngeal carcinoma ( exclude adenocarcinoma ) , stage III IV evidence distant metastatic disease ( M0 ) No lung , bone , liver metastasis proven within 42 day registration : CT scan nucleotide study chest chest xray liver bone scan alkaline phosphatase great institutional upper limit normal ( ULN ) , clinically indicate liver scan SGOT great institutional ULN PATIENT CHARACTERISTICS : Age : Any age Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 75,000/mm3 Hepatic : Not specify Renal : Creatinine great 1.6 mg/dL AND/OR Creatinine clearance least 50 mL/minute Other : Not pregnant nursing Women/men reproductive potential must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No previous chemotherapy primary site node Endocrine therapy : Not specify Radiotherapy : No previous radiotherapy ( except nonmelanomatous skin cancer outside radiation therapy treatment volume ) Surgery : No previous surgery primary site node</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>stage III nasopharyngeal cancer</keyword>
	<keyword>stage IV nasopharyngeal cancer</keyword>
</DOC>